AMYLIN'S EXENATIDE LAR PRICING IN HALF OF STOCK'S VALUE

Merrill Lynch upgraded Amylin Pharmaceuticals to "neutral" from "sell," citing more reasonable share prices, but said it continues to be wary of risks related to experimental drug exenatide LAR.

Forbes (http://www.forbes.com/technology/sciences/2006/02/13/amylin-exenatide-0213markets10.html?partner=rss)

(http://www.bloomberg.com/apps/news?pid=10000102&sid=aYW4iYmkPTMc&refer=uk)